Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
MercoPress1d
COVID-19 booster shots are better if specific brands are used
COVID-19 vaccines used in Brazil are from three different technology platforms. Besides Pfizer's, which contains synthetic RNA from SARS-CoV-2 ... booster dose with an mRNA vaccine such as Moderna ...
Moderna norovirus vaccine trial on hold by US FDA over neurological side effect
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
COVID-19 Vaccine
Follow the latest COVID-19 Vaccine news stories and headlines. Get breaking news alerts when you download the ABC News App and subscribe to COVID-19 Vaccine notifications.
Fact Check: Moderna began clinical trials of COVID vaccine in 2020, not 2017
Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
Moderna beats on revenue but loses more than expected as it scales down manufacturing
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
Nasdaq4d
Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline
Moderna MRNA ... 2024 compared with $2.8 billion in the year-ago quarter. Per management, the decrease was primarily due to the earlier launch of the updated COVID-19 vaccine in the United States ...
Yahoo Finance4d
Moderna norovirus vaccine trial on hold by US FDA over neurological side effect
(Reuters) -Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case ... expected quarterly loss of $2.91 per share, compared to ...